[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

US20180007924A9 - Homogenous cannabis compositions and methods of making the same - Google Patents

Homogenous cannabis compositions and methods of making the same Download PDF

Info

Publication number
US20180007924A9
US20180007924A9 US15/084,954 US201615084954A US2018007924A9 US 20180007924 A9 US20180007924 A9 US 20180007924A9 US 201615084954 A US201615084954 A US 201615084954A US 2018007924 A9 US2018007924 A9 US 2018007924A9
Authority
US
United States
Prior art keywords
composition
oil
cannabis
cannabinoid
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US15/084,954
Other languages
English (en)
Other versions
US20170280740A1 (en
Inventor
Jeremy H. Goldstein
Justin Eric Singer
Adrian Verwolf
Garret Nicodemus
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
5071 Inc
Original Assignee
5071 Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 5071 Inc filed Critical 5071 Inc
Priority to CA2985332A priority Critical patent/CA2985332C/fr
Priority to CA3176674A priority patent/CA3176674A1/fr
Priority to PCT/US2016/025044 priority patent/WO2016186735A1/fr
Priority to US15/084,954 priority patent/US20180007924A9/en
Assigned to 5071, INC. reassignment 5071, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: GOLDSTEIN, Jeremy H., SINGER, Justin Eric
Assigned to 5071, INC. reassignment 5071, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: NICODEMUS, GARRET, VERWOLF, Adrian
Publication of US20170280740A1 publication Critical patent/US20170280740A1/en
Publication of US20180007924A9 publication Critical patent/US20180007924A9/en
Priority to US16/571,610 priority patent/US11980204B2/en
Priority to US18/340,572 priority patent/US20230413845A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
    • A23F3/00—Tea; Tea substitutes; Preparations thereof
    • A23F3/06—Treating tea before extraction; Preparations produced thereby
    • A23F3/14—Tea preparations, e.g. using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
    • A23P10/00—Shaping or working of foodstuffs characterised by the products
    • A23P10/40—Shaping or working of foodstuffs characterised by the products free-flowing powder or instant powder, i.e. powder which is reconstituted rapidly when liquid is added
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1664—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • This disclosure relates to the cannabis industry.
  • the disclosure relates to cannabis compositions for use in the making beverages, methods of making beverages, and beverages.
  • Cannabis has a long history of being consumed for many purposes and in many forms.
  • the psychoactive effects of cannabis are well known, however the medical benefits are just as useful. Treating glaucoma, pain management, appetite stimulation and easing anxiety are just a few of the potential benefits.
  • the source of these effects are in the cannabinoids, a class of compounds found exclusively in the cannabis plant.
  • cannabinoids a class of compounds found exclusively in the cannabis plant.
  • THC tetrahydrocannabniol
  • CBD cannabidiol
  • CBD is also another major cannabinoid comprising up to 40% of cannabis extract and could have as many health benefits as THC.
  • a common method is alcohol extraction. Using a solvent to extract the cannabinoids and then evaporating the alcohol leaving a resin. Further extraction and evaporation can yield a product that is closer to a solid.
  • Another common method for the purposes of making edibles is placing the cannabis leaves in butter, heavy cream, oil, etc and then heating to extract the cannabinoids. The end product is then used as an ingredient in baking or cooking which usually results in a high caloric food due to the fat needed to extract the cannabinoids.
  • Cannabinoids are soluble in fats and alcohols. Which is why when making cannabis tea the cannabinoids have to be already extracted. Just placing cannabis leaves in hot water will not effectively extract any of the vital cannabinoids.
  • the cannabis arts do not have homogenous cannabis beverages.
  • Existing cannabis beverages include large amounts of caloric material.
  • Existing cannabis beverages are not capable of providing consistent cannabinoid concentrations, especially at low cannabinoid concentrations.
  • these new cannabis compositions are beverages, such as tea.
  • these new cannabis compositions are dehydrated beverages, such as powders or crystalline forms, which can be mixed with other components, like tea, and added to water.
  • the disclosed cannabis compositions are homogenous. In one embodiment, the disclosed cannabis compositions include a surfactant and a carrier oil. In one embodiment, the disclosed cannabis compositions are consistent with respect to cannabinoid amount. In one embodiment, the disclosed cannabis compositions are low-calorie cannabis beverages, such as low calorie cannabis teas.
  • compositions comprising:
  • cannabinoid refers to a compound that acts on the cannabinoid receptor.
  • the compositions are low does compositions having 0.1 to 10 mg of cannabinoid. In some embodiments, the composition comprises between 0.5 to 5 mg.
  • cannabinoid can be used, such as more than 10 mg, for example 20-500 mg or 50-200 mg.
  • cannabinoids are tetrahydrocannabinol, cannabidiol, cannabigerol, cannabichromene, cannabicyclol, cannabivarin, cannabielsoin, cannabicitran, cannabigerolic acid, cannabigerolic acid monomethylether, cannabigerol monomethylether, cannabigerovarinic acid, cannabigerovarin, cannabichromenic acid, cannabichromevarinic acid, cannabichromevarin, cannabidolic acid, cannabidiol monomethylether, cannabidiol-C 4 , cannabidivarinic acid, cannabidiorcol, delta-9-tetrahydrocannabinolic acid A, delta-9-tetrahydrocannabinolic
  • THC tetrahydrocannabinol
  • CBD canbidiol
  • surfactant refers to a compound that lowers the surface tension between two liquids or between a liquid and solid.
  • Surfactants can be anionic, cationic, non-ionic and amphoteric.
  • Examples of surfactants are ammonium lauryl sulfate, dioctyl sodium sulfosuccinate, perflurooctanoic acid, potassium lauryl sulfate, soap, sodium dodecyl sulfate, sodium dodecylbenzenesulfonate, sodium laureth sulfate, sodium lauroyl sarcosinate, sodium myreth sulfate, sodium pareth sulfate, sodium stearate, perflurobutanesulfonic acid, perfluorononanoic acid, perlurooactanesulfonic acid, benzalkonium chloride, benzethonium chloride, bronidox, dimethyldioctade
  • polysorbate 80 refers to a compound having the following structure:
  • glycol monostearate refers to a compound having the following structure:
  • carrier oil refers to an oil that can be used to form a homogenized mixture with cannabis oil. Examples include coconut oil, palm oil, palm kernel oil, hemp oil, caproic acid and caprylic acid.
  • carrier oils within the context of this disclosure is medium chain triglycerides.
  • coconut oil is another example of a carrier oil within the context of this disclosure.
  • hemp oil is another example of a carrier oil within the context of this disclosure.
  • coconut oil means oil extracted from the kernel or meat of coconuts.
  • coconut is the fruit of the coconut palm.
  • coconut oil is noted for it's high saturated content. Examples include lauric acid, myristic acid, palmitic acid, and decanoic acid.
  • hemp oil refers to oil obtained from hemp seeds. Hemp seeds come from a variety of the Cannabis sativa plant that does not contain a high amount of tetrahydrocannabinol.
  • the oil is about 80% essential fatty acids. Examples include linolenic acid, omega-6, alpha-linolenic acid, and omega-3.
  • the composition comprises a cannabinoid, a surfactant, a carrier oil, and a sugar alcohol.
  • sugar alcohol refers to alcohols prepared from sugars with the general chemical formula HOCH 2 (CHOH) n CH 2 OH.
  • examples include glycerol, erythritol, threitol, arabitol, xylitol, mannitol, ribitol, mannitol, galacitol, fucitol, inositol, volemitol, maltitol, lacitol, malootetraitol, polyglycitol, sorbitol, iditol, isomalt, and maltotriitol.
  • sugar alcohols within the context of this disclosure include glycerol/glycerin or sorbitol.
  • glycol refers to a compound having the following structure:
  • sorbitol refers to a compound having the following structure:
  • the composition disclosed herein comprises a cannabinoid, a surfactant, a carrier oil, and a gelling agent.
  • gelling agent means a substance that dissolves in the liquid phase and forms a weak cohesive internal structure. Examples include natural gums, starches, pectins, agar-agar, and gelatin.
  • gelatin refers to a gelling agent derived from the collagen of various all byproducts.
  • the composition comprises a cannabinoid, a surfactant, a carrier oil, and has less than 10 mass % water. In one embodiment, the composition is a solid. In one embodiment, the composition is a granual.
  • the term “less than 10 mass % water” means less than 10% of water, by mass, of the composition.
  • the composition comprises a cannabinoid, a surfactant, a carrier oil, and has more than 95 mass % water.
  • the term “more than 95 mass % water” means less than 95% of water, by mass, of the composition.
  • the composition comprises a cannabinoid, a surfactant, a carrier oil, and a flavoring agent.
  • flavoring agent means a compound that adds a flavor to a composition.
  • flavoring agents include amyl acetate, benzaldehyde, ethyl butyrate, methyl anthranilate, methyl salicylate, fumaric acid, diacetyl, cinnamaldehyde, ethyl propionate, limonene, ethyl decadienoate, allyl hexanoate, ethyl maltol, ethylvanillin, and methyl salicylate.
  • the composition comprises a coloring agent.
  • coloring agent means any substance that adds or changes the color of the substance to which the coloring agent is added.
  • examples of the term coloring agent include any dye, pigment or substance that imparts color when it is added to food or drink.
  • the coloring agent can be natural or non-natural. Such agents come in many forms, including liquids, powders, gels, dyes, lakes, and pastes.
  • one or more coloring agents can be added to the compositions of this disclosure to match the coloring between two ingredients.
  • brownish color is added to a compositions comprising a cannabinoid, a surfactant, and a carrier oil in order to make the said compositions take on the color of natural tea.
  • the composition comprises a cannabinoid, a surfactant, a carrier oil, and tea.
  • tea are tea leaves.
  • tea is meant to include any composition that is similar or labeled as tea, either natural or synthetic. Tea refers to both artificially flavored and/or artificially colored compositions in addition to all forms of natural tea leaves.
  • the cannabis compositions are brown granules.
  • leaf refers to forms of the plant Camellia sinensis.
  • the composition comprises less than 4 grams of caloric mass. In one embodiment the caloric mass is less than 2 grams.
  • caloric mass means mass metabolized by humans to generate energy. Examples include carbohydrates and proteins which give 4 cal/gram and fats which give 9 cal/gram.
  • the composition comprises 0.5 to 5 mg of the cannabinoid is present in a consistent amount, having less than 0.2 mg of deviation across sample portions of the composition.
  • the term“consistent amount” means a collection of samples would all have relatively similar amounts of the cannabinoid. Similar means limited amount of deviation in the mass of the cannabinoid. For example, if a collection of compositions were analyzed to determine the mass of cannabinoid present, each sample in that collection would have a similar mass of cannabinoid present in relation to the total amount of each composition.
  • the composition comprises:
  • the gram amounts of ingredients depend on the batch size. Gram amounts for batches can be determined by following the mixing guidelines below.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
US15/084,954 2015-05-18 2016-03-30 Homogenous cannabis compositions and methods of making the same Abandoned US20180007924A9 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CA2985332A CA2985332C (fr) 2015-05-18 2016-03-30 Compositions de cannabis homogenes et methodes de preparation
CA3176674A CA3176674A1 (fr) 2015-05-18 2016-03-30 Compositions de cannabis homogenes et methodes de preparation
PCT/US2016/025044 WO2016186735A1 (fr) 2015-05-18 2016-03-30 Compositions de cannabis homogènes et leurs procédés de production
US15/084,954 US20180007924A9 (en) 2015-05-18 2016-03-30 Homogenous cannabis compositions and methods of making the same
US16/571,610 US11980204B2 (en) 2015-05-18 2019-09-16 Cannabis compositions and methods of making the same
US18/340,572 US20230413845A1 (en) 2015-05-18 2023-06-23 Cannabis compositions and methods of making the same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562163316P 2015-05-18 2015-05-18
US15/084,954 US20180007924A9 (en) 2015-05-18 2016-03-30 Homogenous cannabis compositions and methods of making the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US16/571,610 Continuation US11980204B2 (en) 2015-05-18 2019-09-16 Cannabis compositions and methods of making the same

Publications (2)

Publication Number Publication Date
US20170280740A1 US20170280740A1 (en) 2017-10-05
US20180007924A9 true US20180007924A9 (en) 2018-01-11

Family

ID=57320177

Family Applications (3)

Application Number Title Priority Date Filing Date
US15/084,954 Abandoned US20180007924A9 (en) 2015-05-18 2016-03-30 Homogenous cannabis compositions and methods of making the same
US16/571,610 Active US11980204B2 (en) 2015-05-18 2019-09-16 Cannabis compositions and methods of making the same
US18/340,572 Pending US20230413845A1 (en) 2015-05-18 2023-06-23 Cannabis compositions and methods of making the same

Family Applications After (2)

Application Number Title Priority Date Filing Date
US16/571,610 Active US11980204B2 (en) 2015-05-18 2019-09-16 Cannabis compositions and methods of making the same
US18/340,572 Pending US20230413845A1 (en) 2015-05-18 2023-06-23 Cannabis compositions and methods of making the same

Country Status (3)

Country Link
US (3) US20180007924A9 (fr)
CA (2) CA3176674A1 (fr)
WO (1) WO2016186735A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020073032A1 (fr) * 2018-10-06 2020-04-09 Capaldi Francesco Systèmes et procédés permettant de combiner des cannabinoïdes et une solution à base de sucre, et de créer des comprimés à dissolution buccale
WO2020176806A1 (fr) * 2019-02-27 2020-09-03 3-Delta, Inc. Compositions qui contiennent une matière végétale lipophile et un tensioactif, et procédés associés
US11980204B2 (en) 2015-05-18 2024-05-14 5071, Inc. Cannabis compositions and methods of making the same

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180116240A1 (en) * 2015-12-09 2018-05-03 Poviva Tea, Llc Stable ready-to-drink beverage compositions comprising lipophilic active agents
ES2981120T3 (es) * 2017-07-14 2024-10-07 5071 Inc Composiciones de cannabinoides y métodos de preparación de las mismas
US20190022028A1 (en) * 2017-07-21 2019-01-24 Annabelle Manalo Cannabidiol-enriched caprylic acid
NZ764977A (en) * 2017-10-30 2023-01-27 Whistler Tech Corp Terpene enrichment methods and systems
CA3128712A1 (fr) * 2018-11-30 2020-06-04 Canopy Growth Corporation Formulations hydrosolubles, methodes de fabrication et utilisation
US20200352191A1 (en) * 2019-05-06 2020-11-12 Karl Lonsbery Edible formulations and uses thereof
US10919828B1 (en) * 2020-02-14 2021-02-16 Aicardo Roa-Espinosa Process for manufacturing cannabidiol
MX2022013090A (es) 2020-04-20 2022-11-14 Poviva Corp Composiciones y metodos para el suministro mejorado de agentes antivirales.
US20210329938A1 (en) * 2020-04-27 2021-10-28 Mikki West Cannabis beverage compositions
US20210393540A1 (en) * 2020-06-19 2021-12-23 NuRevelation, LLC Nanoparticle-encapsulated cannabinoids and methods for making and using same
BR112022025912A2 (pt) * 2020-06-19 2023-05-02 Nurevelation Llc Canabinoides encapsulados em nanopartículas e métodos para produzir e usar os mesmos

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US28919A (en) * 1860-06-26 Improvement in plows
GB9726916D0 (en) 1997-12-19 1998-02-18 Danbiosyst Uk Nasal formulation
US6730330B2 (en) * 2001-02-14 2004-05-04 Gw Pharma Limited Pharmaceutical formulations
US7713440B2 (en) * 2003-10-08 2010-05-11 Lyotropic Therapeutics, Inc. Stabilized uncoated particles of reversed liquid crystalline phase materials
WO2006012176A1 (fr) * 2004-06-24 2006-02-02 Virginia Commonwealth University Cannabinoides solubles dans l'eau
PT1903866E (pt) 2005-11-07 2016-06-09 Murty Pharmaceuticals Inc Distribuição melhorada de tetra-hidrocanabinol
US9265724B2 (en) * 2005-11-07 2016-02-23 Ram B. Murty Oral dosage form of tetrahydrocannabinol and a method of avoiding and/or suppressing hepatic first pass metabolism via targeted chylomicron/lipoprotein delivery
US20140357708A1 (en) * 2005-11-07 2014-12-04 Murty Pharmaceuticals, Inc. Oral dosage form of tetrahydrocannabinol and a method of avoiding and/or suppressing hepatic first pass metabolism via targeted chylomicron/lipoprotein delivery
US20090095164A1 (en) * 2007-05-17 2009-04-16 Salvatore Albert Celeste Method of enhancing beverages by means of a unique microencapsulated delivery system
JP5739344B2 (ja) 2008-10-31 2015-06-24 ザ ユニヴァーシティー オブ ミシシッピ Δ−９−ｔｈｃ−アミノ酸エステルを含む組成物及び調製方法
CN101904401A (zh) 2010-07-09 2010-12-08 云南龙润茶业集团有限公司 一种茶凝胶软糖
US20120095087A1 (en) 2010-10-15 2012-04-19 Keith Hyatt Enhanced products by sustainable processes for medicinal use
US20120231083A1 (en) * 2010-11-18 2012-09-13 The Board Of Trustees Of The University Of Illinois Sustained release cannabinoid medicaments
WO2013009928A1 (fr) 2011-07-11 2013-01-17 Organic Medical Research Formulations de cannabinoïdes
WO2013165251A1 (fr) * 2012-05-03 2013-11-07 Echo Pharmaceuticals B.V. Isolat de plante de cannabis comprenant du ∆9-tétrahydrocannabinol et procédé pour la préparation d'un tel isolat
US9345771B2 (en) * 2012-10-04 2016-05-24 Insys Development Company, Inc. Oral cannabinoid formulations
CN103110582A (zh) 2013-03-04 2013-05-22 上海医药工业研究院 大麻酚类化合物微乳剂及其制备方法
WO2015017751A1 (fr) * 2013-08-01 2015-02-05 Intertape Polymer Corp. Rubans adhésifs en silicone et procédé de masquage les utilisant
US9326967B2 (en) 2013-08-22 2016-05-03 Stephen C. Perry Vaporizable cannabinoid compositions
WO2015074137A1 (fr) 2013-11-20 2015-05-28 Mary Lynch Compositions et méthodes de traitement de l'inflammation oculaire et de la douleur
US9259449B2 (en) * 2014-01-07 2016-02-16 Joshua Michael Raderman Method for modifying THC content in a lipid-based extract of cannabis
WO2015117011A1 (fr) * 2014-01-31 2015-08-06 Pocket Tea, Llc Composition pharmaceutique pour administration orale
US20170340562A9 (en) * 2014-05-12 2017-11-30 Hddc Holdings Llc Cannabinoid caffeinated drinks, powder, beans, and cannabinoid loose tea leaf
EP3152115B1 (fr) * 2014-06-06 2021-05-05 Canntrust Inc. Méthode de préparation d'un contentant à usage unique contenant du cannabis
EP3858364A1 (fr) 2014-06-11 2021-08-04 Poviva Corp. Compositions d'aliments et de boissons dans lesquelles ont été infusées des cannabinoïdes, et leurs procédés d'utilisation
US10307397B2 (en) 2014-07-28 2019-06-04 Concept Matrix Solutions Oral dissolvable film that includes plant extract
US20160058866A1 (en) * 2014-09-02 2016-03-03 Ronald D. Sekura Alternative solutions for the administration of cannabis derived botanical products
US10016363B2 (en) 2014-09-18 2018-07-10 Virun, Inc. Pre-spray emulsions and powders containing non-polar compounds
MX2021010033A (es) 2014-12-12 2022-08-25 Ojai Energetics Pbc Composiciones microencapsuladas de cannabinoides.
US10238745B2 (en) * 2015-01-31 2019-03-26 Constance Therapeutics, Inc. Cannabinoid composition and products including α-tocopherol
US9629886B2 (en) 2015-02-24 2017-04-25 Ers Holdings, Llc Method for conducing concentrated cannabis oil to be stable, emulsifiable and flavorless for use in hot beverages and resulting powderized cannabis oil
CA3089686A1 (fr) * 2015-03-10 2016-09-15 Nanosphere Health Sciences, Llc Administration de medicaments nanoparticulaires comprenant des lipides liquides et des cannabinoides encapsules dans une seule couche de phospholipides essentiels
CA3176674A1 (fr) 2015-05-18 2016-11-24 5071, Inc. Compositions de cannabis homogenes et methodes de preparation
CA3003120A1 (fr) 2015-10-26 2017-05-04 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Formulations de cannabinoides
US9937147B2 (en) 2015-10-29 2018-04-10 NBDD, Inc. Edible base product composition
CA2952335A1 (fr) 2015-12-19 2017-06-19 Delta 9 Gardening B.V. Formulations d'administration therapeutique et systemes renfermant des cannabinoides et des terpenes
AU2018283411B2 (en) 2017-06-16 2021-04-29 Sorse Technology Corporation Preparing stable liquid emulsion forms of plant extract
ES2981120T3 (es) 2017-07-14 2024-10-07 5071 Inc Composiciones de cannabinoides y métodos de preparación de las mismas

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11980204B2 (en) 2015-05-18 2024-05-14 5071, Inc. Cannabis compositions and methods of making the same
WO2020073032A1 (fr) * 2018-10-06 2020-04-09 Capaldi Francesco Systèmes et procédés permettant de combiner des cannabinoïdes et une solution à base de sucre, et de créer des comprimés à dissolution buccale
WO2020176806A1 (fr) * 2019-02-27 2020-09-03 3-Delta, Inc. Compositions qui contiennent une matière végétale lipophile et un tensioactif, et procédés associés

Also Published As

Publication number Publication date
CA3176674A1 (fr) 2016-11-24
US20170280740A1 (en) 2017-10-05
WO2016186735A8 (fr) 2017-06-01
US20230413845A1 (en) 2023-12-28
CA2985332A1 (fr) 2016-11-24
US11980204B2 (en) 2024-05-14
CA2985332C (fr) 2023-01-03
WO2016186735A1 (fr) 2016-11-24
US20200008441A1 (en) 2020-01-09

Similar Documents

Publication Publication Date Title
US11980204B2 (en) Cannabis compositions and methods of making the same
Stavrou et al. Polyphenols in carobs: A review on their composition, antioxidant capacity and cytotoxic effects, and health impact
Seal Quantitative HPLC analysis of phenolic acids, flavonoids and ascorbic acid in four different solvent extracts of two wild edible leaves, Sonchus arvensis and Oenanthe linearis of North-Eastern region in India
Ghanbari et al. Valuable nutrients and functional bioactives in different parts of olive (Olea europaea L.)—a review
Mateos et al. New lipophilic tyrosyl esters. Comparative antioxidant evaluation with hydroxytyrosyl esters
Abe et al. Comparison of phenol content and antioxidant capacity of nuts
Ahmad-Qasem et al. Influence of olive leaf processing on the bioaccessibility of bioactive polyphenols
Rao et al. Rapid extraction of andrographolide from Andrographis paniculata Nees by three phase partitioning and determination of its antioxidant activity
Cerda-Tapia et al. Valorization of pomace powder obtained from native Mexican apple (Malus domestica var. rayada): chemical, techno-functional and antioxidant properties
CN103652859B (zh) 一种具有抗氧化功能的保健食品及其制备方法
JP2004091392A (ja) 水分散用水難溶性成分含有組成物および飲料
Okolo et al. Hexane extract of Dacryodes edulis fruits possesses anti-diabetic and hypolipidaemic potentials in alloxan diabetes of rats
Cáceres-Jiménez et al. UHPLC-HRMS spectrometric analysis: Method validation and plasma and urinary metabolite identification after mango pulp intake
Zompra et al. Metabolite and bioactive compounds profiling of meteora Sea buckthorn berries through high-resolution NMR analysis
EP3297617A1 (fr) Compositions de cannabis homogènes et leurs procédés de production
AU2018338611A1 (en) Edible cannabinoid compositions
Nnadi et al. Antioxidant and antidiabetic potentials of a dimethoxylated flavone obtained from Helianthus annuus L. leaf extract
JP2007526299A (ja) 新規なアビエタンジテルペノイド系化合物、及び榧抽出物、またはそれから分離したアビエタンジテルペノイド系化合物またはテルペノイド系化合物を有効成分とする心臓循環系疾患の予防及び治療用組成物
Fayek et al. Metabolome classification of olive by‐products from different oil presses providing insights into its potential health benefits and valorization as analyzed via multiplex MS‐based techniques coupled to chemometrics
KR101153870B1 (ko) 뉴라미니데이즈 억제활성을 가지는 들깨 추출물
KR101868732B1 (ko) 폴리페놀 추출용 조성물 및 이를 이용한 케나프 추출물의 제조방법
Hewageegana et al. Proximate analysis and standardization of leaves: Leptadenia reticulata (Retz) Wight and Arn (Jeevanti)
Abdallah et al. Useful bioactive compounds from olive tree by-products (Leaves, Branches, Fruits)
Hong et al. Effects of different polarity of onion skin extracts on antioxidative properties and non‐volatile profiles
Ordaz-Trinidad et al. Patents on phytochemicals: methodologies of extraction, application in food and pharmaceutical industry

Legal Events

Date Code Title Description
AS Assignment

Owner name: 5071, INC., COLORADO

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GOLDSTEIN, JEREMY H.;SINGER, JUSTIN ERIC;REEL/FRAME:038138/0547

Effective date: 20160330

AS Assignment

Owner name: 5071, INC., COLORADO

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:VERWOLF, ADRIAN;NICODEMUS, GARRET;REEL/FRAME:042035/0827

Effective date: 20170306

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION